Unknown

Dataset Information

0

Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076).


ABSTRACT: Although bevacizumab (Avastin®) has been approved as an antiangiogenic agent against some cancers, the efficacy is transient and unsatisfactory in other cancers most likely owing to the presence of alternative proangiogenic factors. Therefore, simultaneous blocking of several proangiogenic factors may be a promising strategy for antiangiogenic cancer therapeutics. Accordingly, neuropilin-1 (NRP1) is an attractive target because it serves as a multifunctional receptor for the vascular endothelial growth factor (VEGF) family. Here, we aimed to generate and test an anti-VEGFA and anti-NRP1 dual-targeting bispecific antibody (named as IDB0076) by genetic fusion of an NRP1-targeting peptide to the C-terminus of the bevacizumab heavy chain. Similar to the parental antibody (bevacizumab), IDB0076 suppressed VEGFA-induced migration of human endothelial cells. In contrast, IDB0076 inhibited endothelial-cell migration induced by other angiogenesis growth factors and manifested a more potent antitumor activity than that of bevacizumab in a murine tumor xenograft model. When toxicity was preliminarily evaluated in cynomolgus monkeys, IDB0076 showed no substantial adverse effects, e.g., the absence of noticeable nephrotoxicity, which has previously been documented for the combination therapy of bevacizumab and an anti-NRP1 antibody. Thus, VEGFA-and-NRP1 dual-targeting bispecific antibody IDB0076 may be a potent and safe anticancer agent worthy of further preclinical and clinical studies.

SUBMITTER: Ko JH 

PROVIDER: S-EPMC7356919 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076).

Ko Jong-Hee JH   Kwon Hyuk-Sang HS   Kim Bomin B   Min Gihong G   Shin Chorong C   Yang Seok-Woo SW   Lee Seong Wook SW   Lee Youngmin Y   Hong Dahae D   Kim Yong-Sung YS  

Biomolecules 20200617 6


Although bevacizumab (Avastin<sup>®</sup>) has been approved as an antiangiogenic agent against some cancers, the efficacy is transient and unsatisfactory in other cancers most likely owing to the presence of alternative proangiogenic factors. Therefore, simultaneous blocking of several proangiogenic factors may be a promising strategy for antiangiogenic cancer therapeutics. Accordingly, neuropilin-1 (NRP1) is an attractive target because it serves as a multifunctional receptor for the vascular  ...[more]

Similar Datasets

| S-EPMC7205277 | biostudies-literature
| S-EPMC6188753 | biostudies-literature
| S-EPMC4966847 | biostudies-literature
| S-EPMC9666938 | biostudies-literature
| S-EPMC6949033 | biostudies-literature
2017-06-23 | GSE100431 | GEO
| S-EPMC7931223 | biostudies-literature
2023-09-30 | GSE239693 | GEO
| S-EPMC9371702 | biostudies-literature